The antifibrotic drug halofuginone inhibits proliferation and collagen production by human leiomyoma and myometrial smooth muscle cells

Fertility and Sterility

Volumn 93, Issue 4, 2010, Pages 1290-1298

  Grudzien, Meagan M ^a   Low, Philip Steven ^b   Manning, Peter C ^b   Arredondo, Melissa ^a   Belton Jr , Robert J ^a   Nowak, Romana A ^a,b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

antifibrotic; collagen; halofuginone; leiomyoma; myometrium

Indexed keywords

CASPASE 3; CASPASE 7; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; HALOFUGINONE; MESSENGER RNA; THYMIDINE; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ARTICLE; CELL ASSAY; CELL PROLIFERATION; CELL TYPE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; COMPARATIVE STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; HYSTERECTOMY; LEIOMYOMA; MYOMETRIUM; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER;

APOPTOSIS; CELL PROLIFERATION; COLLAGEN TYPE I; COLLAGEN TYPE III; FEMALE; FIBROSIS; GROWTH INHIBITORS; HUMANS; LEIOMYOMA; MYOCYTES, SMOOTH MUSCLE; MYOMETRIUM; PIPERIDINES; QUINAZOLINONES; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS;

EID: 77049102168     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.11.018     Document Type: Article

References (39)

1. Walker C.L., and Stewart E.A. Uterine fibroids: the elephant in the room. Science 308 (2005) 1589-1592
2. Chavez N.F., and Stewart E.A. Medical treatment of uterine fibroids. Clin Obstet Gynecol 44 (2001) 372-384
3. Buttram Jr. V.C., and Reiter R.C. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 36 (1981) 433-445
4. Zhao S.Z., Wong J.M., and Arguelles L.M. Hospitalization costs associated with leiomyoma. Clin Therap 21 (1999) 563-575
5. Nowak R.A. Identification of new therapies for leiomyomas: what in vitro studies can tell us. Clin Obstet Gynecol 44 (2001) 327-334
6. Stewart E.A. Uterine fibroids. Lancet 357 (2001) 293-298
7. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature 425 (2003) 577-584
8. Derynck R., and Feng X.H. TGF-beta receptor signaling. Biochim Biophys Acta 1333 (1997) F105-F150
9. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1 (2000) 169-178
10. Murphy L.J., and Ballejo G. Growth factor and cytokine expression in the endometrium. In: Findlay J.K. (Ed). Molecular biology of the female reproductive system (1994), Academic Press, San Diego 457
11. Tang X.M., Dou Q., Zhao Y., McLean F., Davis J., and Chegini N. The expression of transforming growth factor-betas and TGF-beta receptor mRNA and protein and the effect of TGF-betas on human myometrial smooth muscle cells in vitro. Mol Hum Reprod 3 (1997) 233-240
12. Lee B.S., and Nowak R.A. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab 86 (2001) 913-920
13. Arici A., and Sozen I. Transforming growth factor-β3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril 73 (2000) 1006-1011
14. Pines M., Vlodavsky I., and Nagler A. Halofuginone: from veterinary use to human therapy. Drug Dev Res 50 (2000) 371-378
15. Granot I., Halevy O., Hurwitz S., and Pines M. Halofuginone: an inhibitor of collagen type I synthesis. Biochim Biophys Acta 1156 (1993) 107-112
16. McGaha T.L., Phelps R.G., Spiera H., and Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 118 (2002) 461-470
17. Nagler A., Miao H.Q., Aingorn H., Pines M., Genina O., and Vlodavsky I. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Arterioscler Thromb Vasc Biol 17 (1997) 194-202
18. Pines M., Snyder D., Yarkoni S., and Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 9 (2003) 417-425
19. Xavier S., Piek E., Fujii M., Javelaud D., Mauviel A., Flanders K.C., et al. Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J Biol Chem 279 (2004) 15167-15176
20. Nagler A., Firman N., Feferman R., Cotev S., Pines M., and Shoshan S. Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Respir Crit Care Med 154 (1996) 1082-1086
21. Gavish Z., Pinthus J.H., Barak V., Ramon J., Nagler A., Eshhar Z., et al. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 51 (2002) 73-83
22. Leiba M., Cahalon L., Shimoni A., Lider O., Zanin-Zhorov A., Hecht I., et al. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells. J Leukoc Biol 80 (2006) 399-406
23. Haran N., Leschinski L., Pines M., and Rapoport J. Inhibition of rat renal fibroblast proliferation by halofuginone. Nephron Exp Nephrol 104 (2006) e35-e40
24. Nagler A., Ohana M., Shibolet O., Shapira M.Y., Alper R., Vlodavsky I., et al. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Eur J Cancer 40 (2004) 1397-1403
25. Chegini N., Luo X., Ding L., and Ripley D. The expression of Smads and transforming growth factor beta receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. Mol Cell Endocrinol 209 (2003) 9-16
26. Popov Y., Patsenker E., Bauer M., Niedobitek E., Schulze-Krebs A., and Schuppan D. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem 281 (2006) 15090-15098
27. Clark D.A., and Coker R. Transforming growth factor-beta (TGF-beta). Int J Biochem Cell Biol 30 (1998) 293-298
28. Fujita M. [Histological and biochemical studies of collagen in human uterine leiomyomas]. Hokkaido Igaku Zasshi 60 (1985) 602-615
29. Stewart E.A., Friedman A.J., Peck K., and Nowak R.A. Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J Clin Endocrinol Metab 79 (1994) 900-906
30. Brooke B.S., Karnik S.K., and Li D.Y. Extracellular matrix in vascular morphogenesis and disease: structure versus signal. Trends Cell Biol 13 (2003) 51-56
31. Henriet P., Zhong Z.D., Brooks P.C., Weinberg K.I., and DeClerck Y.A. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci USA 97 (2000) 10026-10031
32. Koyama H., Raines E.W., Bornfeldt K.E., Roberts J.M., and Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 87 (1996) 1069-1078
33. Pozzi A., Wary K.K., Giancotti F.G., and Gardner H.A. Integrin alpha1beta1 mediates a unique collagen-dependent proliferation pathway in vivo. J Cell Biol 142 (1998) 587-594
34. Vogel W.F., Aszodi A., Alves F., and Pawson T. Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. Mol Cell Biol 21 (2001) 2906-2917
35. Hou G., Vogel W.F., and Bendeck M.P. Tyrosine kinase activity of discoidin domain receptor 1 is necessary for smooth muscle cell migration and matrix metalloproteinase expression. Circ Res 90 (2002) 1147-1149
36. Vogel W., Gish G.D., Alves F., and Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell 1 (1997) 13-23
37. Zaitseva M., Vollenhoven B.J., and Rogers P.A. In vitro culture significantly alters gene expression profiles and reduces differences between myometrial and leiomyoma smooth muscle cells. Mol Hum Reprod 12 (2006) 187-207
38. Gross K.L., Neskey D.M., Manchanda N., Weremowicz S., Kleinman M.S., Nowak R.A., et al. HMGA2 expression in uterine leiomyomata and myometrium: quantitative analysis and tissue culture studies. Genes Chromosomes Cancer 38 (2003) 68-79
39. Loy C.J., Evelyn S., Lim F.K., Liu M.H., and Yong E.L. Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferators-activated receptor ligand, pioglitazone. Mol Hum Reprod 11 (2005) 561-566